Treatment Sequencing in HER2+ mBC: Real-World Data & Key Considerations in Third-Line Treatment Selection

Opinion
Video

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab versus T-DM1, considering factors such as resistance mechanisms, administration preferences, and side effect management.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
Related Content